Önenli-Mungan N, KörD, Karabay-Bayazıt A, Cengiz N, YavuzS, NoyanA, CeylanerG, Şeker-Yılmaz B, TopaloğluAK, YükselB, AnaratA. Genotypic and phenotypic features of the cystinosis patients from the South Eastern part of Turkey. Turk J Pediatr 2016; 58: 362-370.We have conducted this study for the purposes of demonstrating the spectrum of mutations and of identifying their effects on the phenotype, with a particular focus on the clinical course, prognosis and response to treatment. A total of 25 patients from 20 families, who have been treated and followed up after being diagnosed with cystinosis. Nine patients were identified with mutations of homozygous c.451A>G, 7 patients with homozygous c.681G>A, 6 patients with homozygous c.834_842del, 2 patients with homozygous c.18_21delGACT and 1 patient with compound heterozygous for c.451A>G/ c.1015G>A. The c.834_842del mutation identified in six patients from four families has not been previously identified.Progression to renal failure occurred earlier in the patients identified with the new mutation, despite treatment. Larger patient series are required to demonstrate the genotypic properties of the patients with cystinosis and their relationship with the clinical course.
___
1. Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med 2002; 347: 111-121.
2. Gahl WA, Thoene J, Schneider JA. Cystinosis: a disorder of lysosomal membrane transport. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B. (Eds) The Metabolic and Molecular Bases of Inherited Disease 8th ed McGraw-Hill, New-York 2001; 5085-5108.
3. Bois E, Feingold, Frenay P, Briard M-L. Infantile cystinosis in France: genetics, incidence, geographic distribution. J Med Genet 1976; 13: 434-438.
4. Levtchenko EN, Van Dael CM, De Graaf-Hess AC, et al. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatr Nephrol 2006; 21: 110-113.
5. Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab 2000; 71: 100-120.
6. Langman CB, Moore ES, Thoene JG, Schneider JA. Renal failure in a sibship with late-onset cystinosis. J Pediatr 1985; 107: 755-756.
7. Wilmer MJ, Schoeber JP, Van den Heuvel LP, Levtchenko EN. Cystinosis: practical tools for diagnosis and treatment. Pediatr Nephrol 2011; 26: 205-215.
8. Servais A, Moriniere V, Grunfeld JP, et al. Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping. Clin J Am Soc Nephrol 2008; 3: 27- 35.
9. Kimonis VE, Troendle J, Rose SR, et al. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab 1995; 80: 3257-3261.
10. Kleta R, Bernardini I, Ueda M, et al. Long-term followup of well-treated nephropathic cystinosis patients. J Pediatr 2004; 145: 555-560.
11. Town M, Jean G, Cherqui S, et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 1998; 18: 319-324.
12. Shotelersuk V, Larson D, Anikster Y, et al. CTNS mutations in an American-based population of cystinosis patients. Am J Hum Genet, 1998; 63: 1352-1362.
13. Attard M, Jean G, Forestier L, et al. Severity of phenotype in cystinosis varies with mutations in the CTNS gene: predicted effect on the model of cystinosin. Hum Mol Genet 1999; 8: 2507-2514.
14. Topaloglu R, Vilboux T, Coşkun T, et al. Genetic basis of cystinosis in Turkish patients: a single-center experience. Pediatr Nephrol 2012; 27: 115-121.
15. Shahkarami S, Galehdari H, Ahmadzadeh A, Babaahmadi M, Pedram M. The first Molecular genetics analysis of individuals suffering from nephropatic cystinosis in the Southwestern Iran. Nefrologia 2013; 33: 308-15.
16. Aldahmesh MA, Humeidan A, Almojalli HA, et al. Characterization of CTNS mutations in Arab patients with cystinosis. Ophthalmic Genet 2009; 30: 185-189.
17. Mason S, Pepe G, Dall'Amico R, et al. Mutational spectrum of the CTNS gene in Italy. Eur J Hum Genet 2003; 11: 503-508.